Eventhough FLT3 inhibitors are promising in treating FLT3-ITD mutant AML patients, the limitations should not be ignored: drug resistance that often occurs within 1–3 months after initial remission responses, resulting in disease relapse and treatment failure (23). This evidence concerns the gene FLT3 and acute myeloid leukemia.